Cargando…

Intratumor heterogeneity and cell secretome promote chemotherapy resistance and progression of colorectal cancer

The major underlying cause for the high mortality rate in colorectal cancer (CRC) relies on its drug resistance, to which intratumor heterogeneity (ITH) contributes substantially. CRC tumors have been reported to comprise heterogeneous populations of cancer cells that can be grouped into 4 consensus...

Descripción completa

Detalles Bibliográficos
Autores principales: Källberg, Julia, Harrison, Alexandra, March, Valerie, Bērziņa, Santa, Nemazanyy, Ivan, Kepp, Oliver, Kroemer, Guido, Mouillet-Richard, Sophie, Laurent-Puig, Pierre, Taly, Valérie, Xiao, Wenjin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10160076/
https://www.ncbi.nlm.nih.gov/pubmed/37142595
http://dx.doi.org/10.1038/s41419-023-05806-z
_version_ 1785037208744361984
author Källberg, Julia
Harrison, Alexandra
March, Valerie
Bērziņa, Santa
Nemazanyy, Ivan
Kepp, Oliver
Kroemer, Guido
Mouillet-Richard, Sophie
Laurent-Puig, Pierre
Taly, Valérie
Xiao, Wenjin
author_facet Källberg, Julia
Harrison, Alexandra
March, Valerie
Bērziņa, Santa
Nemazanyy, Ivan
Kepp, Oliver
Kroemer, Guido
Mouillet-Richard, Sophie
Laurent-Puig, Pierre
Taly, Valérie
Xiao, Wenjin
author_sort Källberg, Julia
collection PubMed
description The major underlying cause for the high mortality rate in colorectal cancer (CRC) relies on its drug resistance, to which intratumor heterogeneity (ITH) contributes substantially. CRC tumors have been reported to comprise heterogeneous populations of cancer cells that can be grouped into 4 consensus molecular subtypes (CMS). However, the impact of inter-cellular interaction between these cellular states on the emergence of drug resistance and CRC progression remains elusive. Here, we explored the interaction between cell lines belonging to the CMS1 (HCT116 and LoVo) and the CMS4 (SW620 and MDST8) in a 3D coculture model, mimicking the ITH of CRC. The spatial distribution of each cell population showed that CMS1 cells had a preference to grow in the center of cocultured spheroids, while CMS4 cells localized at the periphery, in line with observations in tumors from CRC patients. Cocultures of CMS1 and CMS4 cells did not alter cell growth, but significantly sustained the survival of both CMS1 and CMS4 cells in response to the front-line chemotherapeutic agent 5-fluorouracil (5-FU). Mechanistically, the secretome of CMS1 cells exhibited a remarkable protective effect for CMS4 cells against 5-FU treatment, while promoting cellular invasion. Secreted metabolites may be responsible for these effects, as demonstrated by the existence of 5-FU induced metabolomic shifts, as well as by the experimental transfer of the metabolome between CMS1 and CMS4 cells. Overall, our results suggest that the interplay between CMS1 and CMS4 cells stimulates CRC progression and reduces the efficacy of chemotherapy.
format Online
Article
Text
id pubmed-10160076
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-101600762023-05-06 Intratumor heterogeneity and cell secretome promote chemotherapy resistance and progression of colorectal cancer Källberg, Julia Harrison, Alexandra March, Valerie Bērziņa, Santa Nemazanyy, Ivan Kepp, Oliver Kroemer, Guido Mouillet-Richard, Sophie Laurent-Puig, Pierre Taly, Valérie Xiao, Wenjin Cell Death Dis Article The major underlying cause for the high mortality rate in colorectal cancer (CRC) relies on its drug resistance, to which intratumor heterogeneity (ITH) contributes substantially. CRC tumors have been reported to comprise heterogeneous populations of cancer cells that can be grouped into 4 consensus molecular subtypes (CMS). However, the impact of inter-cellular interaction between these cellular states on the emergence of drug resistance and CRC progression remains elusive. Here, we explored the interaction between cell lines belonging to the CMS1 (HCT116 and LoVo) and the CMS4 (SW620 and MDST8) in a 3D coculture model, mimicking the ITH of CRC. The spatial distribution of each cell population showed that CMS1 cells had a preference to grow in the center of cocultured spheroids, while CMS4 cells localized at the periphery, in line with observations in tumors from CRC patients. Cocultures of CMS1 and CMS4 cells did not alter cell growth, but significantly sustained the survival of both CMS1 and CMS4 cells in response to the front-line chemotherapeutic agent 5-fluorouracil (5-FU). Mechanistically, the secretome of CMS1 cells exhibited a remarkable protective effect for CMS4 cells against 5-FU treatment, while promoting cellular invasion. Secreted metabolites may be responsible for these effects, as demonstrated by the existence of 5-FU induced metabolomic shifts, as well as by the experimental transfer of the metabolome between CMS1 and CMS4 cells. Overall, our results suggest that the interplay between CMS1 and CMS4 cells stimulates CRC progression and reduces the efficacy of chemotherapy. Nature Publishing Group UK 2023-05-05 /pmc/articles/PMC10160076/ /pubmed/37142595 http://dx.doi.org/10.1038/s41419-023-05806-z Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Källberg, Julia
Harrison, Alexandra
March, Valerie
Bērziņa, Santa
Nemazanyy, Ivan
Kepp, Oliver
Kroemer, Guido
Mouillet-Richard, Sophie
Laurent-Puig, Pierre
Taly, Valérie
Xiao, Wenjin
Intratumor heterogeneity and cell secretome promote chemotherapy resistance and progression of colorectal cancer
title Intratumor heterogeneity and cell secretome promote chemotherapy resistance and progression of colorectal cancer
title_full Intratumor heterogeneity and cell secretome promote chemotherapy resistance and progression of colorectal cancer
title_fullStr Intratumor heterogeneity and cell secretome promote chemotherapy resistance and progression of colorectal cancer
title_full_unstemmed Intratumor heterogeneity and cell secretome promote chemotherapy resistance and progression of colorectal cancer
title_short Intratumor heterogeneity and cell secretome promote chemotherapy resistance and progression of colorectal cancer
title_sort intratumor heterogeneity and cell secretome promote chemotherapy resistance and progression of colorectal cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10160076/
https://www.ncbi.nlm.nih.gov/pubmed/37142595
http://dx.doi.org/10.1038/s41419-023-05806-z
work_keys_str_mv AT kallbergjulia intratumorheterogeneityandcellsecretomepromotechemotherapyresistanceandprogressionofcolorectalcancer
AT harrisonalexandra intratumorheterogeneityandcellsecretomepromotechemotherapyresistanceandprogressionofcolorectalcancer
AT marchvalerie intratumorheterogeneityandcellsecretomepromotechemotherapyresistanceandprogressionofcolorectalcancer
AT berzinasanta intratumorheterogeneityandcellsecretomepromotechemotherapyresistanceandprogressionofcolorectalcancer
AT nemazanyyivan intratumorheterogeneityandcellsecretomepromotechemotherapyresistanceandprogressionofcolorectalcancer
AT keppoliver intratumorheterogeneityandcellsecretomepromotechemotherapyresistanceandprogressionofcolorectalcancer
AT kroemerguido intratumorheterogeneityandcellsecretomepromotechemotherapyresistanceandprogressionofcolorectalcancer
AT mouilletrichardsophie intratumorheterogeneityandcellsecretomepromotechemotherapyresistanceandprogressionofcolorectalcancer
AT laurentpuigpierre intratumorheterogeneityandcellsecretomepromotechemotherapyresistanceandprogressionofcolorectalcancer
AT talyvalerie intratumorheterogeneityandcellsecretomepromotechemotherapyresistanceandprogressionofcolorectalcancer
AT xiaowenjin intratumorheterogeneityandcellsecretomepromotechemotherapyresistanceandprogressionofcolorectalcancer